Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...
Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these ...
Background: Axillary lymph node dissection has been an established surgical component of breast cancer management since the development of the radical mastectomy. However, the contribution of surgical ...
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in ...
A model has been developed to predict the risk of hidden lymph node metastasis, helping prevent lymphedema, or arm swelling, ...
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
The 2026 ESMO annual meeting featured a prostate cancer proffered paper session and a discussant presentation by Dr. Nicholas van As discussing two abstracts “Perioperative apalutamide + ADT with ...
SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results